Experts lead participants in a discussion of the complexities, risks, and benefits of treating hepatorenal syndrome-acute kidney injury (HRS-AKI) in patients with acute-on-chronic liver failure being considered for liver transplantation. Topics include treatment strategies, implications for waitlist prioritization, and use of terlipressin.

Connect. Collaborate. Engage.
Join fellow hepatology associates for an informal and energizing meet-up at The Liver Meeting. Whether you're focused on research, clinical care, or both, this is your chance to network with peers, spark new ideas, and explore collaborative opportunities in a relaxed setting. Don’t miss it!

This course reviews timely topics regarding the management of alcohol use disorder (AUD), obesity, and food addiction. Experts highlight the striking behavioral and neurobiologic similarities between AUD and food addiction; key differences that impact clinical management; and the mechanisms underlying addiction in both contexts. Drawing on lessons from AUD treatment, the implications of food addiction in MASLD and alcohol-associated liver disease (ALD) are explored along with tips for effectively counseling patients on diet and lifestyle modifications. Using a case-based learning platform, presenters discuss multidisciplinary treatment strategies for both AUD and food addiction, and explore integration of addiction medicine principles into hepatology clinical practice. Speakers further highlight the complexities of addiction management, addressing challenges such as relapse, patient adherence, and the role of emerging therapies in improving outcomes. Experts also provide an update on the evolving clinical definition of obesity and the latest advancements in pharmacological treatments, particularly in the context of MASLD and ALD, including the incorporation of novel anti-obesity medications into hepatology practice to optimize patient outcomes. An interactive workshop highlighting the role of motivational interviewing for effecting behavioral change in obesity and AUD management follows. Participants practice key techniques for engaging patients in meaningful conversations about lifestyle modifications and treatment adherence. Drawing from successful models in primary care, experts share practical strategies for overcoming patient resistance and enhancing motivation for long-term health improvements.

NOTE: Continuing education credits earned at this session count as group 2 credits toward the American Board of Obesity Medicine qualifications for certification via the CME pathway.

In this interactive session, experts focus on the diagnosis of clinically significant hypersplenism, related clinical complications, and management approaches including emerging interventional approaches to clinically important hypersplenism. 

RNA nanomedicine has emerged as a groundbreaking approach for safely delivering genetic instructions into target cells, enabling their reprogramming without degradation. Its significance was underscored during the COVID-19 pandemic with the successful deployment of mRNA-based vaccines formulated using lipid nanoparticles. These nanoparticles, available in various formulations, act as carriers to transport RNA directly into target cells for therapeutic action. Patisiran and lumasiran—2 FDA-approved RNA interference (RNAi) agents delivered via lipid nanoparticles (RNA nanotherapeutics)—exemplify this new generation of targeted therapies. These treatments have significantly reduced the need for liver transplantation in patients with genetic conditions such as amyloidosis and hyperoxaluria. Consequently, referrals for liver transplantation due to these metabolic disorders have dramatically declined, highlighting the transformative potential of RNA nanomedicine in clinical practice. In this workshop, experts review the transformative world of RNA nanomedicine; explore its role in delivering genetic instructions with unparalleled precision; discover how advancements in lipid nanoparticle (LNP) formulations are enabling breakthrough therapies; and gain insights into the latest clinical applications that are reshaping treatment paradigms, such as reducing the need for liver transplantation in genetic and metabolic disorders. 

Begin your experience at The Liver Meeting® with an evening of mingling, refreshments, and a warm welcome from AASLD as you explore the Exhibit Hall. This casual gathering provides the opportunity to meet new colleagues and hear from industry leaders.

Sponsored by: Mirum Pharmaceuticals
 

Join experts providing a comprehensive overview of MetALD, ie, combined metabolic dysfunction-associated and alcohol-associated liver disease. Presenters highlight key considerations for developing robust research programs; leveraging biomarkers and omics technologies; and understanding the interplay between alcohol use, metabolic dysfunction, and liver disease progression. Speakers discuss emerging insights into risk stratification, cohort development, and the relationship between MetALD and HCC. The workshop aims to integrate translational and clinical research approaches, equipping attendees with knowledge to enhance precision medicine strategies in MetALD.

Join your SIG Meet-Up, where you can connect with professionals who share your research and clinical interests! Enjoy light snacks, fun games, and great conversations in a relaxed, informal setting—perfect for networking and building new connections.

• Liver Cell Biology SIG 
• Liver Fibrosis & Cirrhosis 
• Alcohol-associated Liver Disease 
• Liver Transplantation and Surgery 
• Portal Hypertension 

Experts provide an overview of the latest innovations in study design in MetALD-induced liver disease, including study endpoints. Presenters explore how to design and conduct effective cohort studies, large database studies, and clinical trials. Topics include the role of investigator-initiated cohort studies, large national database studies, and clinical trials in MetALD with discussion of funding opportunities, monitoring, and conducting these studies with a focus on early-stage investigators. This interactive session provides an opportunity to discuss study methodologies, existing studies, and protocols with the moderators.

Experts provide an overview of the latest innovations in study design in MetALD-induced liver disease, including study endpoints. Presenters explore how to design and conduct effective cohort studies, large database studies, and clinical trials. Topics include the role of investigator-initiated cohort studies, large national database studies, and clinical trials in MetALD with discussion of funding opportunities, monitoring, and conducting these studies with a focus on early-stage investigators. This interactive session provides an opportunity to discuss study methodologies, existing studies, and protocols with the moderators.